Natixis Advisors LLC Has $2.94 Million Position in Glaukos Corporation (NYSE:GKOS)

Key Points

• Natixis Advisors LLC has reduced its stake in Glaukos Corporation by 12.9%, now holding approximately 29,871 shares worth $2.94 million.
• Glaukos reported a 29.7% year-over-year increase in quarterly revenue, totaling $124.12 million, while beating earnings per share estimates.
• According to analysts, Glaukos has a consensus rating of "Moderate Buy" with an average price target of $127.42.

Natixis Advisors LLC lessened its holdings in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 12.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,871 shares of the medical instruments supplier's stock after selling 4,428 shares during the period. Natixis Advisors LLC owned approximately 0.05% of Glaukos worth $2,940,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of GKOS. O Shaughnessy Asset Management LLC lifted its holdings in shares of Glaukos by 4.6% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 4,410 shares of the medical instruments supplier's stock valued at $661,000 after purchasing an additional 192 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Glaukos by 15.4% during the 4th quarter. Russell Investments Group Ltd. now owns 13,965 shares of the medical instruments supplier's stock valued at $2,094,000 after purchasing an additional 1,863 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of Glaukos by 1.8% during the 4th quarter. Federated Hermes Inc. now owns 28,224 shares of the medical instruments supplier's stock valued at $4,232,000 after purchasing an additional 501 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Glaukos by 4.9% during the 4th quarter. Invesco Ltd. now owns 1,458,635 shares of the medical instruments supplier's stock valued at $218,708,000 after purchasing an additional 68,310 shares in the last quarter. Finally, FIL Ltd acquired a new stake in Glaukos in the 4th quarter valued at approximately $1,063,000. Institutional investors own 99.04% of the company's stock.

Glaukos Stock Down 3.6%

Shares of NYSE:GKOS traded down $3.20 during trading on Friday, hitting $84.80. 812,044 shares of the company were exchanged, compared to its average volume of 1,276,931. The stock has a market cap of $4.86 billion, a price-to-earnings ratio of -51.39 and a beta of 0.78. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The firm has a fifty day moving average price of $97.18 and a two-hundred day moving average price of $105.77. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. The business had revenue of $124.12 million for the quarter, compared to analyst estimates of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%. The firm's revenue was up 29.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.52) EPS. As a group, research analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Needham & Company LLC dropped their target price on Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Stephens dropped their target price on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Stifel Nicolaus dropped their target price on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. BTIG Research reissued a "buy" rating on shares of Glaukos in a research report on Monday, July 14th. Finally, Truist Financial reissued a "buy" rating and issued a $135.00 target price (down previously from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $127.42.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.